drugset / Trial / NCT03406949
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.
Timeline
- Start
- 2018-02-27
- Primary completion
- 2022-04-27
- Completion
- 2022-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGD009 | Protein / enzyme biologic | — | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |